CTC
TVRD

Central Trust Company’s Tvardi Therapeutics TVRD Stock Holding History

Central Trust Company’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1
Closed – – 1302
2018
Q2 		$0 Buy
+1
New +$508 ﹤0.01% 1348
2017
Q4 		– Sell
-7
Closed -$3K – 1386
2017
Q3 		$3K Hold
7
– – ﹤0.01% 1133
2017
Q2 		$4K Hold
7
– – ﹤0.01% 1100
2017
Q1 		$5K Buy
+7
New +$3.74K ﹤0.01% 1044

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Central Trust Company's TVRD Position: Q3 2018 in Review

Central Trust Company sold out of Tvardi Therapeutics (TVRD) in Q3 2018, closing a stake of 1 share.

Central Trust Company first reported a position in TVRD in Q1 2017 and held it in 4 quarters. The position peaked at $5K in Q1 2017. 146 funds tracked by Wall St. Rank hold TVRD as of Q3 2018.

  • Central Trust Company reported no remaining Tvardi Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Central Trust Company sold 1 Tvardi Therapeutics share in Q3 2018.
  • Central Trust Company first reported a position in Tvardi Therapeutics in Q1 2017 and held it in 4 quarters.
  • Central Trust Company's Tvardi Therapeutics position peaked at $5K in Q1 2017.
  • 146 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2018.

Based on Central Trust Company's 13F filing for Q3 2018, filed 4 Oct 2018.